» Articles » PMID: 21557041

Medical Management of Patients with Brain Tumors

Overview
Specialty Neurology
Date 2011 May 11
PMID 21557041
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with brain tumors require meticulous attention to medical issues resulting from their disease or its therapy. The following specific issues are the ones most frequently arising in the purview of neurologists: (1) Vasogenic edema: Corticosteroids should be used in divided doses in the minimum amount required to control symptoms and should be tapered as quickly as possible. Some patients may require long-term steroid supplementation, and symptoms of adrenal insufficiency should be investigated with 8 AM: cortisol measurement and treated with appropriate repletion. (2) Seizures: Patients with brain tumors should receive antiepileptic drugs only if they have had seizures, and the drugs should be chosen to minimize cognitive effects and interactions with concurrently administered chemotherapy. Levetiracetam is an excellent choice for patients with partial seizures and is available both orally and parenterally. Lamotrigine is another reasonable choice but requires slow titration. (3) Venous thromboembolism: All brain tumor patients should receive perioperative venous thrombosis prophylaxis with compression boots and enoxaparin or dalteparin. Lifelong treatment with low molecular weight heparinoids or warfarin is required for those developing venous thromboembolism. (4) Other problems: Long-term survivors of brain tumors should be monitored indefinitely for cognitive problems, endocrine dysfunction, and development of secondary neoplasms. Modafinil can improve mood and attention impairments.

Citing Articles

Ultrasensitive System for Electrophysiology of Cancer Cell Populations: A Review.

Rocha P, Elghajiji A, Tosh D Bioelectricity. 2021; 1(3):131-138.

PMID: 34471815 PMC: 8370286. DOI: 10.1089/bioe.2019.0020.


The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Bai H, Xiong L, Han B Onco Targets Ther. 2017; 10:2335-2340.

PMID: 28490892 PMC: 5415007. DOI: 10.2147/OTT.S129809.


Incidence, risk factors and outcomes of seizures occurring after craniotomy for primary brain tumor resection.

Al-Dorzi H, Alruwaita A, Marae B, Alraddadi B, Tamim H, Ferayan A Neurosciences (Riyadh). 2017; 22(2):107-113.

PMID: 28416781 PMC: 5726815. DOI: 10.17712/nsj.2017.2.20160570.


Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.

He Y, Sun W, Wang Y, Ren S, Li X, Li J Onco Targets Ther. 2016; 9:2409-14.

PMID: 27143936 PMC: 4844452. DOI: 10.2147/OTT.S102236.


Management of elderly patients with gliomas.

Gallego Perez-Larraya J, Delattre J Oncologist. 2014; 19(12):1258-67.

PMID: 25342314 PMC: 4257742. DOI: 10.1634/theoncologist.2014-0170.


References
1.
Nghiemphu P, Green R, Pope W, Lai A, Cloughesy T . Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008; 10(3):355-60. PMC: 2563058. DOI: 10.1215/15228517-2008-009. View

2.
Lee J, Bromfield E, Kesari S . Antiemetic properties of the antiepileptic drug levetiracetam. N Engl J Med. 2008; 359(17):1853. DOI: 10.1056/NEJMc0806761. View

3.
Mattson R . Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis. 2006; 1 Suppl 1:S10-7. View

4.
Oeffinger K, Mertens A, Sklar C, Kawashima T, Hudson M, Meadows A . Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355(15):1572-82. DOI: 10.1056/NEJMsa060185. View

5.
Meyer G, Badenhoop K . [Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy]. Med Klin (Munich). 2003; 98(5):266-70. DOI: 10.1007/s00063-003-1255-z. View